Advanced searches left 3/3

Metastatic Colorectal Cancer - DOAJ

Summarized by Plex Scholar
Last Updated: 27 April 2022

* If you want to update the article please login/register

Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis

Abstract Background In the modern period, the association between metastatic colorectal cancer and venous thromboembolism is vague. In a modern older mCRC cohort, our goal was to investigate the effects of putative risk factors such as newer medications and anti-angiogenic therapy on VTE incidence and survival. Risk factor analysis was conducted using Cox models adjusted for sex, diagnosis age, race, primary tumor location, comorbidity, and prior VTE history, with cancer treatments as time-varying covariates. There were 1306 cases of VTE related to 13. 7% incidence at one year and 20. 3% at three years, with 13. 7% at 1 year and 20. 3% at 3 years. Female sex, African American race, prior VTE history, and right-sided cancers were among the Independent VTE forecastors. Following the diagnosis of mCRC, a diagnosis of mCRC was correlated with inferior OS, the patient had a poorer outlook. Conclusions In this large mCRC cohort, safe systemic therapy, as well as anti-angiogenic therapy, was correlated with decreased VTE risk.

Source link: https://doi.org/10.1002/cam4.4581


The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation

Background: Colourectal cancer is the fourth most common cancer in the United Kingdom after breast, lung, and prostate cancer. Patients with metastatic disease that are physically fit are often treated with first or second-line therapy with active chemotherapy. In conjunction with chemotherapy and cetuximab in combination with chemotherapy and cetuximab in combination with chemotherapy and cetuximab for rats sarcoma wild-type patients who need first-line therapy of metastatic colorectal cancer. Methods: Participants with previously untreated metastatic colorectal cancer with RAS WT status were included in studies if they were randomised controlled trials or systematic reviews of RCTs of cetuximab or panitumumab in participants with previously untreated metastatic colorectal cancer with RAS WT status. Patients with RAS WT's first-line therapy using anti-EGFR therapy in conjunction with chemotherapy appeared to have statistically significant benefits for patients who are RAS WT. Compared to FOLFOX, the RAS WT patients' average cost-effectiveness ratio for cetuximab plus oxaliplatin-based chemotherapy was £104,205 per QALY increased for RAS WT patients compared to FOLFOX; for panitumumab plus FOLFOX, relative to FOLFIRI was £122,554 per QALY increased, while FOLFIRI's average IQ gained was £104,205, per QALY increased for cetuxima gaining, compared to FOLFOX gained, but lost, QALY gained; for compared to FOLFOX gained; for compared to FOLFOX gained; for versus FOLFOX; for RAS WT; and FOLFIRI; and FOLFIRI compared to FOLFIRI compared to FOLFIRI versus FOLFIRI was £122,554 per QALY gained; and FOLFIRI compared with FOLFIRI was £122,554 per QALY gained; and FOLFIRI compared to FOLFI Limitations: The trials included RAS WT populations only as subgroups, not as subgroups. Conclusions: Although cetuximab and panitumumab in combination with chemotherapy appear to be clinically beneficial for RAS WT patients compared to chemotherapy alone, they are expected to be poor value for money if determined by cost-effectiveness standards currently used in the United Kingdom. Funding for the National Institute for Health Research Health Technology Assessment (NIH) is based on the National Institute for Health Information Health Technology Assessment (TWAC).

Source link: https://doi.org/10.3310/hta21380


KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis

Background: Bowel cancer is the third most common cancer in the United Kingdom. If this occurs, the liver tumour may be surgically treated, or chemotherapy may be used to shrink the tumor to make surgery possible. Objectives: To determine the effectiveness and cost-effectiveness of KRAS mutation tests in differentiating adults with metastatic colorectal cancer metastases are limited to the liver and are unresectable, and who may benefit from first-line treatment with cetuximab in combination with standard chemotherapy alone for those who should receive standard chemotherapy alone. The health economic study looked at long-term costs and quality-adjusted life-years associated with various tests and measurements followed by chemotherapy with either standard chemotherapy or cetuximab plus standard chemotherapy. Two studies published reports on the reliability of KRAS mutation testing for predicting response to chemotherapy in patients treated with cetuximab plus standard chemotherapy. Four RCTs published studies on the clinical efficiency of cetuximab plus standard chemotherapy in patients with KRAS wild-type tumors. No significant differences in the treatment effects reported by various studies were found, regardless of which KRAS mutation test was used to select patients. Conclusions: There was no evidence that any one KRAS mutation test was more efficient or cost-effective than any other test. The National Institute for Health Research Health Technology Assessment program is funded by the National Institute for Health Research Health Science Assessment (NIH).

Source link: https://doi.org/10.3310/hta18620


Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis

Many agents have been tested as maintenance therapy for metastatic colorectal cancer, but there is no agreement on the correct dosage. The effect of single-agent capecitabine maintenance therapy on mCRC patients' survival rates was investigated in this study. A comprehensive literature review was conducted as part of pre-specified inclusion and exclusion criteria for randomized controlled trials comparing capecitabine as maintenance monotherapy and active monitoring for mCRC patients. Neither OS improvement nor mortality reduction at 24 months with capecitabine maintenance were found, according to Pooled's statistics. Capecitabine maintenance therapy improved PFS and reduced the risk of progression at 6 months compared to continuous monitoring. Any grade 3 toxicity was more prevalent with maintenance therapy than with observation. Although therapy for patients with mCRC does not improve, single-agent capecitabine as maintenance leads to no OS benefit, but results in a statistically significant rise in PFS despite elevated risk of toxicity.

Source link: https://doi.org/10.1055/s-0042-1744439


Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer

This research sought to analyze KRAS, NRAS, and BRAF mutations in patients with metastatic colorectal cancer with polymerase chain reaction and in-house next-generation sequencing to determine KRAS, NRAS, and BRAF mutations in patients with metastatic colorectal cancer patients with predictive and prognostic outcomes. Patients with mCRC were assessed between August 2017 and June 2019 at a single center in the present study. The overall concordance between NGS and PCR results for detecting KRAS, NRAS, and BRAF mutations was strikingly poor, with only 15 discrepant results between PCR and NGS.

Source link: https://doi.org/10.3390/cimb44040106


Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients

BackgroundThe rechallenge with EGFR inhibitors is a promising treatment for patients of RAS wild type colorectal cancer, but concrete selection criteria are lacking. Both on tumor tissue and on ct-DNA at baseline, as eligible for our analysis, with cetuximab in a RAS and BRAF WT selected population. Our study looked at the liquid biopsy-driven cetuximab rechallenge in a RAS and BRAF WT-choice population. Previous responses to anti-EGFR were correlated with increased mPFS; the anti-EGFR free interval > 14 months; and an anti-EGFR free interval > 16 months were correlated with increased mPFS and reduced mOS; The long anti-EGFR-free period has been extended as a prospective selection criterion for this therapeutic option, in addition to the molecular evaluation by the analysis of ct-DNA for RAS.

Source link: https://doi.org/10.3389/fonc.2022.852583


Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country

The aim of this unicentric research was to assess the sensitivity and safety of TT in patients with refractory mCRC in everyday clinical practice. All patients had neutropeniagrades on 3 of 4; however, only two patients had neutropenia and no deaths were attributable to neutropenia.

Source link: https://doaj.org/article/6662a5908afb425da730166069bc067b


Metastatic colorectal cancer to a primary thyroid cancer

Metastases to the thyroid gland have however been reported to occur occasionally, particularly if normal thyroid tissue structure has been altered. Conclusions Metastatic rectal carcinoma of the thyroid gland and especially a primary thyroid malignancy are rare and unusual. Prognosis is likely to be more dependent on the underlying metastatic disease than on primary thyroid malignancy, so primary care should be tailored to treating and preventing metastatic disease rather than the primary thyroid malignancy.

Source link: https://doi.org/10.1186/1477-7819-6-122


Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer

Abstract Background: Objectives: To assess the palliative role of radiotherapy and determine the success of chemotherapy with palliative RT in patients with a symptomatic pelvic mass of metastatic colorectal cancer. At Samsung Medical Center, 80 patients with a symptomatic pelvic mass of metastatic colorectal cancer were treated with palliative RT from August 1995 to December 2007. In 58 patients, rectal cancer in 58 patients and colon cancer in 22 patients, respectively. The median RT dose was 46. 8 Gy 10 despite the fact that the tumor was expected to be 10 Gy for the biologically equivalent dose. Symptom palliation was diagnosed one month after RT's conclusion. Conclusions RT was a safe palliation treatment in patients with a symptomatic pelvic mass of metastatic colorectal cancer.

Source link: https://doi.org/10.1186/1748-717X-6-52


Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

Abstract Background The anti-VEGF antibody bevacizumab along with an irinotecan or oxaliplatin-based chemotherapy was shown to be more effective than chemotherapy alone in first or second line therapy of metastatic colorectal cancer. The purpose of this investigation was to investigate the effects of bevacizumab combined with FOLFIRI or FOLFOX in mCRCs who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin. The overall response rate among the patients who had previously received the same chemotherapy as that associated with bevacizumab was 37. 7% and 39. 3%, respectively. Conclusions Bevacizumab, FOLFOX, or FOLFIRI, according to the present study, it appears that bevacizumab and selected mCRC patients who did not know it or not get it previously.

Source link: https://doi.org/10.1186/1471-2407-9-347

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions